ArticleFrontiers in pharmacology2024

A case report: Pathological complete response to neoadjuvant lorlatinib for Epithelioid inflammatory myofibroblastic sarcoma with EML4-ALK rearrangement.

Yang Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.